Osteosarcoma from the Unknown to the Use of Exosomes As a Versatile and Dynamic Therapeutic Approach
Overview
Affiliations
The most common primary malignant tumor of bone in children is osteosarcoma (OS). Nowadays, the prognosis and the introduction of chemotherapy in OS have improved survival rates of patients. Nevertheless, the results are still unsatisfactory, especially, in patients with recurrent disease or metastatic. OS chemotherapy has two main challenges related to treatment toxicity and multiple drug resistance. In this way, nanotechnology has developed nanosystems capable of releasing the drug directly at the OS cells and decreasing the drug's toxicity. Exosomes (Exo), a cell-derived nano-sized and a phospholipid vehicle, have been recognized as important drug delivery systems in several cancers. They are involved in a variety of biological processes and are an important mediator of long-distance intercellular communication. Exo can reduce inflammation and show low toxicity in healthy cells. Furthermore, the incorporation of specific proteins or peptides on the Exo surface improves their targeting capability in several clinical applications. Due to their unique structure and relevant characteristics, Exo is a promising nanocarrier for OS treatment. This review intends to describe the properties that turn Exo into an efficient, as well as safe nanovesicle for drug delivery and treatment of OS.
Inflammasome-related gene signatures as prognostic biomarkers in osteosarcoma.
Zhang N, Han Y, Cao H, Wang Q J Cell Mol Med. 2024; 28(9):e18286.
PMID: 38742843 PMC: 11092527. DOI: 10.1111/jcmm.18286.
Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.
Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A Pharmaceutics. 2023; 15(10).
PMID: 37896191 PMC: 10610377. DOI: 10.3390/pharmaceutics15102431.
Omidian H, Mfoafo K Pharmaceutics. 2023; 15(6).
PMID: 37376032 PMC: 10303369. DOI: 10.3390/pharmaceutics15061583.
Exosomes and osteosarcoma drug resistance.
Fu H, Wu Y, Chen J, Hu X, Wang X, Xu G Front Oncol. 2023; 13:1133726.
PMID: 37007086 PMC: 10064327. DOI: 10.3389/fonc.2023.1133726.
Nanosized drug delivery strategies in osteosarcoma chemotherapy.
Chen C, Wang S, Wang J, Yao F, Tang X, Guo W APL Bioeng. 2023; 7(1):011501.
PMID: 36845905 PMC: 9957606. DOI: 10.1063/5.0137026.